Fresh from the European Medicines Agency accepting for filing Biogen/Bio-Thera Solutions’ proposed intravenous formulation tocilizumab biosimilar, the US Food and Drug Administration has agreed to review the Massachusetts-based biotech’s application.
Barring any potential delays, the US race for biosimilar tocilizumab is expected to be tight, with Fresenius Kabi tipping itself...






